MergerLinks Daily Review
MergerLinks
Join a community of 250,000+ M&A professionals. Expand your network and discover new business opportunities.
Welcome to MergerLinks Daily Review.?Sign up here ?to get the full round up of your daily dose of blue-chip M&A news directly to your inbox.
AstraZeneca to acquire Amolyt Pharma from Sofinnova Partners and EQT Life Sciences for $1.05bn. (FS)
Peruvian healthcare firm Auna targets up to $1.1bn valuation in US IPO. (FS)
India's Manipal Health set to buy majority stake in Medica Synergie for $151m.?
You can access today’s complete newsletter?here.?
Scroll down for more…
Stonepeak , an investment firm, completed the acquisition of Textainer , a company that focuses on purchasing, leasing, and resale of marine cargo containers, for $7.4bn.
“Today we embark on Textainer’s exciting next chapter with a renewed commitment to delivering high quality equipment and best-in-class service to our customers worldwide. Over the years, we have established Textainer as our customers’ “first call” for containers, and we look forward to continuing to earn our customers’ trust while growing with them. We’re pleased to have found a great partner in Stonepeak, whose industry expertise and resources position us well to achieve our long-term goals,” Olivier Ghesquiere, Textainer President and CEO.
Stonepeak was advised by 德意志银行 , Simpson Thacher & Bartlett LLP (led by Brian Chisling ) and FGS Global (led by Julie Rudnick ). Textainer was advised by 美国银行 (led by Loli Wu ), 美迈斯 and Joele Frank (led by Lynch, Tim and Jamie Moser ). Financial advisors were advised by Cleary Gottlieb Steen & Hamilton LLP (led by Paul Shim ).
AstraZeneca to acquire Amolyt Pharma from Sofinnova Partners and EQT Life Sciences for $1.05bn. (FS)
阿斯利康 , a pharmaceutical company, agreed to acquire Amolyt Pharma , a global, clinical-stage biopharmaceutical company, from Sofinnova Partners , a European life sciences venture capital firm, and EQT Life Sciences , a healthcare investor, for $1.05bn.?
"Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca. Leading Amolyt’s Series C financing round in January 2023 was an honor. This milestone demonstrates Sofinnova's investment thesis in action, showcasing our commitment to supporting innovative European companies during their critical growth stage. In Amolyt's case, it exemplifies our commitment to supporting a company developing groundbreaking solutions in a later stage of development for rare disease patients,” Cédric Moreau, Sofinnova Partner.
Sofinnova is advised by Havas (led by?Pierluigi Cavarai). Amolyt Pharma is advised by Centerview Partners , 高盛 , Cooley LLP (led by?Laura Berezin?and Marc Recht ), 众达律师事务所 , LifeSci Advisors, LLC (led by Ashley Robinson )?and StrategiesImage (led by Anne Rein ).?
HILTON WORLDWIDE SERVICES LIMITED , a hospitality company that owns luxury and full-service hotels and resorts, agreed to acquire Graduate Hotels , a collection of hotels that reside in dynamic university-anchored towns in the US, from AJ Capital Partners , a private equity firm focusing on hospitality and real estate investments, for $210m.
"Adding Graduate Hotels to our portfolio of award-winning brands accelerates our expansion in the lifestyle space by pairing an existing much-loved brand with the power of Hilton's strong commercial engine to drive growth. We have long had a high bar for adding brands to our portfolio, whether organically or through acquisition, and Graduate will be another driver of growth for us, presenting a unique opportunity to serve more guests in more sought-after destinations. With thousands of colleges and universities around the world, we believe the addressable market for the Graduate brand is 400-500 hotels globally," Chris Nassetta, Hilton President and CEO.
AJ Capital is advised by 德意志银行 .
Peruvian healthcare firm Auna targets up to $1.1bn valuation in US IPO. (FS)
Peruvian healthcare and insurance provider Auna said that it aims for a valuation of up to $1.1bn in its US initial public offering. The company, which operates in 3 Latin American countries and is controlled by private equity firm Enfoca , plans to raise up to $450m by selling about 30m class A shares priced between $13 and $15 each,?Reuters ?reported.
Despite an uneven recovery so far in the year, the US IPO market is expected to rebound in 2024 as bets of a soft landing for the US economy rise, following two weak years driven by geopolitical pressures and the Federal Reserve's quantitative tightening to get a hold on inflation.
India's Manipal Health set to buy majority stake in Medica Synergie for $151m.?
India's Manipal Hospitals (MHEPL) is set to buy a 93% stake in Medica Synergie as early as April for about INR12.50bn ($151m), uniting the two Temasek -backed hospital operators.
Medica Synergie will be integrated into the Manipal portfolio and rebranded, the source said on condition of anonymity. The Singapore-based investment firm holds a 51% stake in Manipal Health and an 87% stake in Medica Synergie,?Reuters ?reported.?
Interested to find more??Sign up here ?to get full round up of your daily dose of blue-chip M&A news directly to your inbox.
You can access today’s complete newsletter here.